Beca J et al., 2019-12: A Canadian cost-utility model of adding docetaxel to androgen deprivation in high-volume metastatic hormone-sensitive prostate cancer found an incremental cost of $25,757 for 1.06 QALYs, an ICER of about $24,226 per QALY, robust below $35,000/QALY in sensitivity analyses.
ADT+D cost an additional $25 757 and produced an extra 1.06 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio (ICER) of $24 226/QALY gained.
Abstract (Results)
Beca J et al., 2019-12: A Canadian cost-utility model of adding docetaxel to androgen deprivation in high-volume metastatic hormone-sensitive prostate cancer found an incremental cost of $25,757 for 1.06 QALYs, an ICER of about $24,226 per QALY, robust below $35,000/QALY in sensitivity analyses. Funder: no industry funding statement appears in the article text; authors are from Cancer Care Ontario, McMaster University, Sunnybrook and University of Toronto (Canadian public health system perspective, costs in CAD). Maker: docetaxel, generic. Comparator: ADT alone. Note the model assumes the CHAARTED/STAMPEDE high-volume benefit; it does not model low-volume disease, where CHAARTED found no benefit. Study type: other.
